Influence of Allopurinol on the Genetic Materials of Ehrlich Ascites Tumor Cells

  • H. Becher
  • B. Puschendorf
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 76B)


From the kinetic parameters of allopurinol with red cell Hypoxanthine-guanine-phosphoribosyltransferase, it is known that allopurinol is a very poor substrate for this enzyme (1) and the quantitative data by ELION (2) demonstrate the unliklihood that allopurinol ribonucleotides are responsible for the feedback inhibition of purine de novo synthesis. However a minimal concentration of nucleotide derivatives of allopurinol could potentially influence the chromatin metabolism of cells.


Purine Metabolism Template Activity Cell Mouse Liver Acid Insoluble Material Polymerase System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Krenitzky, T. A., R. Papaioannou and G. B. Elion J. Biol. Chem., 244, 1263 (1969)Google Scholar
  2. 2.
    Elion, G.B. and D. J. Nelson: Purine metabolism in man. Plenum Press, New York — London 1974, p. 639Google Scholar
  3. 3.
    Marushige, K., J. Bonner J. molec. Biol. 15, 160 (1966)PubMedCrossRefGoogle Scholar
  4. 4.
    Puschendorf, B., H. Wolf, H. Grunicke, Biochem. Pharmacol. 20, 3039 (1971)PubMedCrossRefGoogle Scholar
  5. 5.
    Burgess, R. R., J. biol. Chem. 244, 6166 (1969)Google Scholar
  6. 6.
    Marmur, J J., J. molec. Biol. 3, 208 (1961)CrossRefGoogle Scholar
  7. 7.
    Girard, M.: In L. Grossman, K. Moldave (Hrsg.): Methods of Enzymology. Academic Press, New York — London 1967. S. 586Google Scholar
  8. 8.
    Melli, M., J. O. Bishop, J. molec. Biol. 40, 117 (1969).PubMedCrossRefGoogle Scholar
  9. 9.
    Gillespie, S., D. Gillespie, Biochem. J. 125, 481 (1971)PubMedGoogle Scholar
  10. 10.
    Paul, G., S. Gilmour, J. molec. Biol. 34, 305 (1968)PubMedCrossRefGoogle Scholar
  11. 11.
    Iwamoto, K., D. W. Martin Jr., Biochem. Pharmacol. 23, 3199 (1974)PubMedCrossRefGoogle Scholar
  12. 12.
    Nelson, D. J., C. J. Bugge, H. C. Cransny, G.B. Ellion, Biochem. Pharmacol., 22, 2003 (1973)PubMedCrossRefGoogle Scholar
  13. 13.
    Elion, G. B., A. Kovensky, G. H. Hitchings, E. Metz and R. W. Rundless, Biochem. Pharmacol., 15, 863 (1966)PubMedCrossRefGoogle Scholar
  14. 14.
    Hitchings, G. H. In: Biochemical Aspects of Antimetabo — lites and of Drug Hydroxylation. FEBS Symposium, 16, 11 (1969)Google Scholar
  15. 15.
    Wang, C. J, S. Hayashida, A.M. Pamukcu and G. T. Bryan Canc. Res. 36, 1551 (1976).Google Scholar

Copyright information

© Plenum Press, New York 1977

Authors and Affiliations

  • H. Becher
    • 1
    • 2
  • B. Puschendorf
    • 1
    • 2
  1. 1.Department of MedicineUniversity of FreiburgGermany
  2. 2.Institut of Clinical BiochemistryUniversity of InnsbruckAustria

Personalised recommendations